Kaveri leads CEPA's Global Health team. She has extensive experience of working with global health partnerships and donors on a range of strategic, analytical and review-based assignments. Her core expertise is in strategic reviews and evaluations for global health organisations and their programmes.
Kaveri Kumar is a Partner who leads CEPA's Global Health team. She has around 20 years’ experience working with global health partnerships and donors on a range of strategic, analytical and review-based assignments. Her core expertise is in strategic reviews and evaluations for global health organisations and their programmes, having recently led a review of CEPI’s first business plan to guide its second strategy, an in-depth evaluation of the Global Fund’s support for innovations (product and non-product) and how it might improve its approach going forward, a multi-country review of the Global Fund’s approach to investments in Resilient and Sustainable Systems for Health (RSSH), a strategic review of Gavi’s market shaping policy and a first review of Unitaid’s portfolio on COVID-19.
Kaveri has experience across multiple health sectors: epidemics/ pandemics (COVID-19, cholera, etc.), HIV (having conducted reviews of donor programmes on paediatric HIV treatment, HIV self testing (HIVST), HIV prevention, point of care molecular diagnostics), TB (through reviews of the work of the STOP TB Partnership and TB REACH facility as well as donor funding for scaling up the new and innovative diagnostic of GeneXpert), malaria (through reviews of innovative financing for malaria elimination, donor funding for severe malaria treatments, private sector engagement in malaria) immunisation and child health (including through many years of working with Gavi and WHO), amongst others. Other key experience includes a value for money assessment of the Stop TB Partnership, a meta review of 14 country HSS evaluations to bring out key findings and learnings in support of the design of Gavi’s new Health Systems and Immunisation Strengthening (HSIS) framework, support to the Assistant Director General of the WHO Family, Women’s and Children’s Health Cluster in carrying out a strategic review of the cluster’s priorities, areas of work and organisation, and advice to the PMNCH for a number of years, including in reviewing the RMNCH commodities supply chain. She has expertise in key health technical issues such as innovative health financing, health economics, cost effectiveness and value for money assessments, impact framework development, impact assessment, market dynamics, and has a good understanding of the global health aid architecture and the funding approaches of several institutions.
Kaveri has developed a strong understanding of country health systems through in-country work in Ethiopia, Nigeria, Tanzania, Kenya, Uganda, Mali, Burkina Faso, Ghana, South Africa, India, Bangladesh, Nepal, Indonesia, and Uzbekistan.
Recent News & insights
CEPA supports water, regulatory finance and global health practices with promotions to its partnership
Join us in congratulating Tom Cochrane and Kaveri Kumar on their recent promotions to the firm’s partnership. They join CEPA’s existing global Partners to lead a growing team of more than 50 economic, public and financial policy consulting experts.
CEPA evaluates Unitaid’s $22m investment aimed at supporting access to medicines
Our Global Health team's evaluation of Unitaid's portfolio to 'support access to medicines through innovative use of Trade Related Aspects of Intellectual Property Rights' has been published.
Our report on “Accelerating the Equitable Deployment and Access to Innovations” is published by the Global Fund
A technical evaluation by CEPA's Global Health team, to assess how the Global Fund is performing in terms of supporting innovations.
CEPA’s independent outcome evaluation of CEPI is published
Dr Richard Hatchett, the Chief Executive Officer of The Coalition for Epidemic Preparedness Innovations praises our work, describing it as “a fair, balanced and independent perspective”.
Operational review of Global Fund supported HIV prevention programs for Adolescent Girls and Young Women
CEPA was commissioned by the Global Fund to fight AIDS, Tuberculosis and Malaria (the Global Fund) to conduct an operational review of Global Fund-supported HIV prevention programs for AGYW across 13 priority countries in sub-Saharan Africa.
Independent Outcome Evaluation for The Coalition for Epidemic Preparedness Innovations
Our global health team's Independent Outcome Evaluation has been published by The Coalition for Epidemic Preparedness Innovations (CEPI).
The potential impact of future innovation in support of Unitaid’s strategy
We explored the potential impact of ten promising innovations that Unitaid may support during its 2023-27 strategic period, which could make a significant contribution to advancing global health targets.
Evaluation of Unitaid’s COVID-19 portfolio of investments
CEPA was appointed by Unitaid to undertake a portfolio-level evaluation assessing the contribution of Unitaid’s COVID-19 response and alignment with the ACT-A partnership.
Evaluation of the UNAIDS contribution to Efficient and Sustainable Financing
CEPA was appointed by the UNAIDS Independent Evaluation Office to lead an evaluation of the Joint Programme’s work on equitable, efficient and sustainable financing for the HIV response.
Unitaid HIV self-testing evaluation
End of project evaluation of Unitaid’s HIV Self-testing (HIVST) portfolio.
CEPA evaluates Unitaid’s investments in Hepatitis C
Unitaid has invested more than US$45 million since 2015 in support of improving access to care for hepatitis C. We are pleased to have provided them with a portfolio evaluation and end of grant evaluations.
Unitaid molecular diagnostics portfolio review
CEPA was appointed by Unitaid to conduct a portfolio-level joint end-of-grant evaluation of its investments in Point of Care (POC) molecular diagnostics for HIV.
Evaluation of the Partnership for Maternal, Newborn and Child Health (PMNCH)
CEPA was commissioned by the PMNCH Board to conduct an external evaluation of PMNCH. The evaluation was of strategic importance in the context of developing the next Strategic Plan for PMNCH for the period 2021-2025.
Gavi supply and procurement strategy evaluation
CEPA was appointed by Gavi to conduct an evaluation of the 2016-20 Supply and Procurement Strategy (their market shaping strategy). This large-scale evaluation involved an assessment of the design, implementation and results of the strategy.
TERG / Global Fund HIV primary prevention review
The Global Fund Technical Evaluation Reference Group (TERG) commissioned CEPA to conduct a review of the Global Fund’s investments in HIV primary prevention.
Power of Nutrition Results Framework
CEPA was engaged to evaluate CEPI's results management system. This focused on assessing whether the approach to monitoring and reporting results was relevant, meeting the needs of its donors.
Evaluation of cooperation agreements between health organisations
The Global Fund commissioned CEPA to conduct an evaluation of its Cooperation Agreements with WHO and the Stop TB Partnership on the provision of technical assistance to support the development of country concept notes and grant-making.
Thematic review to assess an approach to investing in resilient & sustainable systems for health
CEPA conducted a thematic review to assess the Global Fund’s current approach to investments in Resilient and Sustainable Systems for Health (RSSH).
Evaluation of community, human rights and gender interventions
CEPA was appointed to develop an evaluation framework and methodology to help the Stop TB Partnership to evaluate its community, human rights and gender focused work.
Evaluation of Gavi health system strengthening support to Nepal
Gavi commissioned an evaluation of its Health System Strengthening (HSS) support to Nepal through the pooled funding mechanism.
Mid-term evaluation of the Unitaid “Self-testing Africa (STAR)” project
CEPA was appointed to review the implementation of the first phase of Unitaid’s HIV self-testing grant to identify areas that worked well and those that worked less well, determine the extent to which the project achieved its intended impacts.